32
Participants
Start Date
June 30, 2011
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
BL-1021
"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
1021
1021
Hadassah Clinical Research Center (HCRC), Jerusalem
Lead Sponsor
BioLineRx, Ltd.
INDUSTRY